| scholarly article | Q13442814 |
| P50 | author | Adriano Chiò | Q30003371 |
| P2093 | author name string | Paola Cassoni | |
| Gaetano Finocchiaro | |||
| Laura Annovazzi | |||
| Michele Lanotte | |||
| Davide Schiffer | |||
| Marta Mellai | |||
| Valentina Caldera | |||
| P433 | issue | 4 | |
| P921 | main subject | hypermethylation | Q106875739 |
| P304 | page(s) | 219-227 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Cancer Genomics and Proteomics | Q15762348 |
| P1476 | title | MGMT promoter hypermethylation in a series of 104 glioblastomas | |
| P478 | volume | 6 |
| Q35173279 | Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres |
| Q33797741 | Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM |
| Q39406816 | Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas |
| Q28388312 | DNA damage response genes and the development of cancer metastasis |
| Q22242858 | Epigenetic changes of DNA repair genes in cancer |
| Q92590931 | Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors |
| Q54584786 | IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. |
| Q49093913 | MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? |
| Q53791485 | MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry. |
| Q48686096 | MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors |
| Q35850389 | MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR |
| Q35827916 | MGMT testing allows for personalised therapy in the temozolomide era. |
| Q38044236 | MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry |
| Q43128475 | O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma |
| Q33804528 | O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction |
| Q42376082 | Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss |
| Q42168209 | Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas |
| Q35828601 | SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy. |
| Q61800092 | Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities |
| Q30353110 | Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression |
Search more.